June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation
Author Affiliations & Notes
  • Karen Tubridy
    Eleven Biotherapeutics, Cambridge, MA
  • Michael H Goldstein
    Eleven Biotherapeutics, Cambridge, MA
    Ophthalmology, Tufts Medical Center, Boston, MA
  • Jennifer Agahigian
    Eleven Biotherapeutics, Cambridge, MA
  • Marianne Magill
    Eleven Biotherapeutics, Cambridge, MA
  • Joseph Kovalchin
    Eleven Biotherapeutics, Cambridge, MA
  • Eric S Furfine
    Eleven Biotherapeutics, Cambridge, MA
  • Abbie Celniker
    Eleven Biotherapeutics, Cambridge, MA
  • Footnotes
    Commercial Relationships Karen Tubridy, Eleven Bio (E), Eleven Bio (I); Michael Goldstein, Eleven bio (E), Eleven Bio (I); Jennifer Agahigian, Eleven Bio (E), Eleven Bio (I); Marianne Magill, Eleven Bio (C); Joseph Kovalchin, Eleven Bio (E), Eleven Bio (I); Eric Furfine, eleven bio (E), eleven bio (I); Abbie Celniker, Eleven Bio (E), Eleven Bio (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4488. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Karen Tubridy, Michael H Goldstein, Jennifer Agahigian, Marianne Magill, Joseph Kovalchin, Eric S Furfine, Abbie Celniker; Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4488.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Interleukin-1 (IL-1) is a key mediator of ocular surface inflammation in dry eye disease (DED) and allergic conjunctivitis (AC). IL-1 is important not only in the initiation and maintenance of the inflammatory response, but also in mediating hypersensitization of peripheral nerves. EBI-005 is an IL-1 receptor inhibitor specifically designed and engineered for topical ophthalmic delivery. EBI-005 has been evaluated in several randomized, controlled clinical trials in DED and AC.

Methods: In a phase 1 healthy volunteer study, 16 subjects were randomized to topical EBI-005 (two different doses) or vehicle control 3x/day for one day. In a double-masked, placebo-controlled phase 2 study, 74 subjects with moderate to severe DED were randomized to receive vehicle or EBI-005 (5 mg/mL or 20 mg/mL) 3x/day for six weeks. In an exploratory, phase 2 study, 159 subjects with moderate to severe AC were randomized to EBI-005 or vehicle control and assigned to one of two different models of AC. Most recently, in a double-masked, placebo-controlled phase 3 study in subjects with moderate to severe DED, 669 subjects were randomized to receive vehicle or EBI-005 5 mg/mL 3x/day for 12 weeks. Safety, biological activity and immunogenicity were assessed.

Results: Topical EBI-005 was generally safe and well tolerated in all studies. No drug specific antibodies have been detected to date. There were no treatment related serious ocular or non-ocular adverse events. In the phase 2 DED study, EBI-005 significantly improved signs and symptoms of DED compared to baseline at week six by up to 30% (p<0.001) and 36% (p<0.001) respectively. In the phase 2 AC study, EBI-005 showed statistically significant (p<0.05), clinically meaningful (>25%) improvement in symptoms of AC including ocular itching, ocular tearing and total nasal symptoms at multiple time points compared to vehicle.

Conclusions: Topical EBI-005 treatment is a promising new therapy for patients with moderate to severe dry eye disease and late phase allergic conjunctivitis. These results further validate the importance of IL-1 blockade in DED and AC. They support continued development of topical EBI-005 in these indications to further characterize the safety and efficacy of the drug in patients with ocular surface inflammation.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.